Both IgM and IgG anti-DNA antibodies are the products of clonally selective B cell stimulation in (NZB x NZW)F1 mice by unknown
Both IgM and IgG Anti-DNA Antibodies 
Are the Products of Clonally Selective B  Cell 
Stimulation in (NZB  x  NZW)FI  Mice 
By David M. Tillman, Nainn-Tsyr  Jou,  Robert J. HiU, 
and Tony N. Marion 
From the Department of Microbiology and Immunology,  and the Molecular Resources Center, 
The  University of Tennessee, Memphis,  Memphis,  Tennessee 38163 
Summary 
Disease activity in systemic lupus erythematosus is closely associated with the appearance  of 
immunoglobulin (Ig)G antibody to native DNA in both humans and mice. Like normal antibody 
responses, the anti-DNA autoantibody first appears as IgM and then switches to IgG. Structural 
studies of IgG anti-DNA suggest that these antibodies are the products of clonally selected, 
specifically stimulated B cells. The origins of the IgM anti-DNA have been less clear. To determine 
whether the earlier appearing IgM anti-DNA antibody in autoimmune mice also derives from 
clonally selected, specifically stimulated B cells or B cells activated by nonselective,  polyclonal 
stimuli, we have analyzed  the molecular and serological  characteristics  of a large number of 
monoclonal IgM anti-DNA antibodies from autoimmune (NZB  x  NZW)F1 mice. We have 
also analyzed IgM and IgG anti-DNA hybridomas obtained from the same individual mice to 
determine how the later-appearing IgG autoantibody may be related to the earlier-appearing  IgM 
autoantibody within an individual mouse. The results demonstrate that: (a) IgM anti-DNA, 
like IgG, has the characteristics of a specifically stimulated antibody; (b) IgM and IgG anti-DNA 
antibodies have similar variable region structures and within individual mice may be produced 
by B cells derived from the same clonal precursors;  (c) recurrent germline and somatically derived 
VH and VL structures may influence the specificity  of anti-DNA monoclonal antibody for denatured 
vs. native DNA; and (d) the results provide a structural explanation for the selective development 
of IgG antibody to native DNA as autoimmunity to DNA progresses  in (NZB  x  NZW)F1 
mice. 
A 
ntibody to DNA is a manifestation of the autoimmune 
disease SLE and plays a demonstrable role in disease 
pathogenesis in both humans (1)  and (NZB  x  NZW)F1 
mice (2, 3). Because of similarities to humans in the develop- 
ment of disease, (NZB  x  NZW)F1 mice have become useful 
experimental models for studying the cellular and molecular 
basis for anti-DNA autoantibody production (3). In partic- 
ular, the availability of hybridoma-derived, anti-DNA mAbs 
from autoimmune mice has provided the opportunity to ana- 
lyze the structural basis for antibody specificity to DNA (4). 
How anti-DNA antibody originates both in human and mouse 
SLE remains obscure,  however. 
Previous experiments from our laboratories  have concen- 
trated on the analysis of interdonal and intraclonal diversity 
of spontaneous anti-DNA antibodies within an individual 
autoimmune (NZB  x  NZW)F1 mouse (5-7).  The results 
from those analyses demonstrated that the IgG anti-DNA 
antibody within an individual autoimmune mouse had all 
the characteristics attributable to clonally selected, secondary. 
immune antibody to specific antigen: IgG isotype, oligoclo- 
nality, and V region somatic mutations among donaUy related 
antibodies.  The results also suggested that the antigen most 
likely to have stimulated such an antibody was DNA. In this 
regard, anti-DNA in (NZB  x  NZW)F1 mice appears to be 
similar to anti-DNA in MRL lpr/Ipr mice (8, 9). However, 
the results  from at least one study on the clonal heteroge- 
neity of anti-DNA antibody within individual autoimmune 
(NZB  x  NZW)F1 mice led to a different conclusion (10). 
Although VH  1 and VL gene representation among the hy- 
bridomas in the previous study was not consistent with a 
polyclonal population,  the  hybridomas were  nevertheless 
clonally diverse. Anti-DNA antibody in autoimmune mice 
undergoes a  spontaneous isotype shift from IgM to IgG 
(11-13).  Analyses of B cell activity in (NZB  x  NZW)F1 
1 Abbreviations  used in this~per: VH, immunoglobulin heavy chain variable 
region; V,, heavy chain variable region gene; VL, immunoglobulin light 
chain variable region; VL, light chain variable region gene. 
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IgM stage of anti-DNA autoantibody production is due to 
polyclonal activation of B cells (15) and that subsequent donal 
selection of IgG anti-DNA-producing B cells occurs subse- 
quent to this event. However, there have been no direct studies 
to determine whether IgM anti-DNA autoantibodies have 
the characteristics of antibody produced by a nonselected, poly- 
clonal population of B cells. Likewise, there have been no 
studies to directly determine the clonal relationship between 
the IgM and IgG anti-DNA autoantibodies within individual 
(NZB  x  NZW)F1 mice. 
The present experiments were proposed to accomplish three 
major goals.  (a) Since there has been some question as to 
whether the autoimmune anti-DNA antibody in (NZB  x 
NZW)F1 mice is generally oligoclonal and characteristic of 
an antigen-stimulated, secondary immune response,  we ex- 
tended our analysis of the clonal diversity of IgG anti-DNA 
antibodies to include seven additional (NZB  x  NZW)F1 
mice.  (b) To determine whether the earlier-appearing  IgM 
anti-DNA antibody is also clonally selected and expresses V 
region structures that are similar to the later-appearing IgG 
anti-DNA  antibodies in  autoimmune (NZB  x  NZW)F1 
mice, a large number of IgM anti-DNA hybridomas from 
four different mice were analyzed. (c) To determine whether 
the IgG anti-DNA antibody within an individual autoim- 
mune mouse is donally related to the earlier-appearing  IgM 
anti-DNA antibody within the same mouse, IgM and IgG 
hybridomas from three individual mice were analyzed. The 
results confirmed our previous results that spontaneous IgG 
anti-DNA antibodies in (NZB  x  NZW)F1 mice are gener- 
ally oligoclonal in origin and have V region structural char- 
acteristics consistent with an antigen-selected derivation. The 
results also demonstrated preferential expression of particular 
V. and VL genes among IgM anti-DNA hybridomas, sug- 
gesting that IgM anti-DNA is also produced by selective B 
cell  stimulation. Finally, the results demonstrated that in 
general IgM and IgG anti-DNA autoantibody-producing B 
cells have structurally similar Ig V regions and that within 
an individual mouse at least some of the IgG anti-DNA 
antibody-producing B cells are derived from the same clonal 
precursors as the IgM anti-DNA antibody-producing B cells. 
Materials  and Methods 
Mice and Generation of Hybridomas.  (NZB  x  NZW)Ft mice 
were purchased from Harlan/Sprague-Dawley (Indianapolis, IN) 
and maintained in a pathogen-free environment within the animal 
facilities at The University of Tennessee, Memphis. Hybridomas 
were generated as described previously (5). A partial splenectomy 
and B cell fusion were performed on one mouse. The mouse was 
completely anesthetized by a combination of intraperitoneal ad- 
ministration of a mixture of xylazine/ketamine/butorphanol (25: 
40:4 mg/kg  body weight) and intermittent inhalation of  metaphane 
throughout the surgical procedure. An incision was made in the 
left flank. The blood vessels in the vascular bundle that enters the 
hilus of the spleen were simnltaneously sealed and cauterized. The 
spleen was cut and the free half removed and used to generate hy- 
bridomas. The abdominal  wall and overlying  skin were closed  with 
surgical staples that were removed 10 d after surgery. The remaining 
half  of  the spleen was removed  at a later date for hybridoma  produc- 
tion by the normal procedure. 
ELISAforAnti-DNA.  The direct-binding, sohd-phase  ELISA 
used to detect anti-DNA-positive  culture wells after the fusion and 
determination of IgH and L isotypes have been described in detail 
(5). Culture wells  were chosen for cloning of  hybridomas  only when 
the relevant culture supernatant produced a relative antibody ac- 
tivity of 3 on a scale of 1 to 10, with 10 being the maximum ac- 
tivity of the  assay (OD~0s i>1.2). The  supernatants were also 
screened for binding to micro-ELISA  plates that were not coated 
with DNA but were treated identically otherwise. The source of 
DNA used for screening hybridoma supernatants was commercial 
calf thymus DNA sheared by sonication. Only hybrids producing 
antibody that was positive on DNA-coated plates and negative for 
binding to plates not coated  with DNA were considered  for cloning. 
This  screening procedure allowed us to  select for hybridomas 
producing both low- and high-avidity IgM and IgG DNA binding 
antibodies, as indicated by the data in Table 1. The assay did not 
discriminate between ssDNA and dsDNA specificity. 
eDNA Sequencing.  The procedures for isolation ofmRNA (16) 
and cDNA sequencing (17), the sequences of the oligonucleotides 
used as primers, and the method for sequence comparisons were 
exactly the same as those we have used previously (7). 
Statistical Analyses.  The numbers ofgermline V. and V~ genes 
that could encode anti-DNA were estimated from the repeat fre- 
quencies of individual Vn and V~ observed among all the different 
clones represented in this study. V. and V~ from individual clones 
were considered to have been derived from the same germline V. 
or V~ if the nucleotide sequences were ~95% homologous. The 
identical pair method of Briles and Carroll (18) was used to obtain 
the  estimates: R  =  N/A,  where N  =  n(n-1)/2;  A  =  , ~I 
czr162  n  =  number  of dependent  sequences; and cxt~" 
number of sequences derived from the same germane sequence i. 
The number of dependent sequences (n) used to calculate the esti- 
mates was adjusted to account for repeat frequencies  among either 
V. or VL sequences that deviated from the expected normal dis- 
tribution  (19). For VL, n  =  42, A  =  14, and N  =  861; there- 
fore, the estimated number of V~ in the anti-DNA repertoire (R) 
is 62 (95% confidence interval [CI]  =  43, 76). For V., n =  55, 
A  =  34, and N  =  1,485; therefore, R  = 44 (95% CI =  31 and 
63). For V.558,  n  =  28, A  --  16,  and N  =  378; therefore, 
R  =  24 (95% CI =  15 and 36). Calculations of the probabilities 
that individual V. or V~ genes, or V,-V~ combinations, would be 
expressed at the indicated frequencies in the absence of selection 
among the population of  hybridomas assumed  a binomial distribu- 
tion for any given V gene (20). 
Results 
Oligoclonalit2/ of leG Anti-ONA Hybridomas.  The criteria 
used in choosing mice for spleen cell fusions to generate hy- 
bridomas were age, serum titer, and isotype of spontaneous 
anti-DNA antibody. Mice used to generate IgM hybridomas 
were <6 mo of age, with IgG anti-DNA titers g90 and IgM 
anti-DNA titers )1,000.  Mice chosen for generating IgG 
anti-DNA hybridomas were usuatly 6-8 mo old or older, 
with serum IgG anti-DNA titers )1,000. Hybridomas gener- 
ated from the fusions were chosen for doming as described 
in Materials and Methods. This procedure was specifically 
chosen so as not to bias the population of hybridomas, par- 
ticularly the IgM, toward either low- or high-affinity anti- 
body. Specificity analyses of the mAbs in competitive ELISAs 
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for hybridomas producing either high- or low-affinity anti- 
body (Table 1). 
During the course of this study, 107 anti-DNA antibody- 
producing hybridomas from 10 different autoimmune (NZB 
x  NZW)F1 mice were generated. Each hybridoma was ana- 
lyzed for VH and VL cDNA nudeotide sequences (Table 1, 
and Figs.  1 and 2) and for isotype and DNA specificity of 
its respective mAb. In each mouse with predominantly IgG 
serum anti-DNA (mouse nos. 17, 111, 163, 10, 74, 83, and 
185), the majority of the IgG hybridomas formed donally 
related groups. For the purpose of comparing the clonal reper- 
toire between IgM and IgG anti-DNA antibodies among 
different individual mice, data in Table 1 and Figs.  1 and 2 
are from only one representative hybridoma of a given donally 
related group. Clones with more than one hybridoma are 
indicated with a "c" designation as part of the clone number 
(e.g., 111-cl). For clones with more than one hybridoma, the 
number of hybridomas in each clone are indicated in Table 
1 and Figs.  1 and 2. Clonal relatedness among relevant hy- 
bridomas was confirmed by nudeotide sequences, particu- 
larly in the junctional regions between V and D and D and 
J  of the heavy chain, and V  and J  of the light chain, and 
by the identity of productive and nonproductive J. and J~ 
rearrangements within each donal member (21). There were 
38 IgM hybridomas from 36 clones, and 69 IgG hybridomas 
from 29 clones (Table 1). Two clones had IgM and IgG hy- 
bridomas from the same clone. The degree to which individual 
clones were expanded in each of the mice was quite variable, 
from single representatives such as 17s.83 and 163.42 to clones 
with nine representative hybridomas such as clones  163-cl 
and 185-cl (Table 1). There was considerable intraclonal vari- 
ation due to somatic mutation in each of the multiple member 
clones ("c" clones in Table 1). Detailed analyses of the muta- 
tions and their effects on the specificity of the respective an- 
tibodies will be presented and discussed elsewhere (N.-T. Jou, 
D. Tillman, R. Hill, and T. Marion, manuscript in prepa- 
ration). 
Recurrent V~ Gene Usage among Both IgM and IgG Anti- 
DNA,  Multiple clones from two or more animals expressed 
at  least  one V.  gene from each  of the  V.558,  V.7183, 
V~Q52, and V.$107 germline V. families (Table 1). For ex- 
ample, 165.14 and 17s.128 each expressed a VH558 family V. 
gene that is nearly identical to the previously identified V. 
for  the  anti-DNA  hybridoma BXW-DNA16  (Fig.  1 A, 
BWDNA16) (22).  Likewise,  17s-cl  and 165.60 had nearly 
identical VK that are also similar to V.558-BWDNAI6, as 
did 10-cl and 17s.166, and 163.72 and 25.12m. Extreme ex- 
amples of identical or nearly identical VH gene expression are 
clones 111.185, 165.27, 165.49, and 17s.83. These clones ex- 
pressed a V~558 family V.  gene very similar  to  that ex- 
pressed by the previously identified anti-DNA hybridoma 
MLR-DNA22 (Fig.  1 A, DNA22) (22).  Eight clones ex- 
pressed a VH previously identified for the hybridoma BXW- 
DNA7 (Fig.  1 A, BWDNA7). In the latter two groups of 
anti-DNA clones, four clones from three different mice (Fig. 
1  A, DNA22) and eight clones from four different mice (Fig. 
1 A, BWDNA7), respectively,  use the same V, gene. 
763  Tillman  et al. 
The repetitive usage of VH genes was apparent among 
both IgM- and IgG-producing clones for each of the V. 
genes described above. For example, 111.185 and 165.27 are 
IgM, and 165.49 and 17s.83 are IgG (Table 1 and Fig.  1 A, 
DNA22). Likewise, 17p.101, 202.80, 202.s.38, 202.135, 202.61, 
165.3m, and one of the hybridomas in 111-cl are IgM (Table 
1 and Fig.  1 A, BWDNAT). All the hybridomas in 111-c2 
and three hyhridomas in 111-cl were IgG. Clone 17ps-c7 had 
two IgM hybridomas and one IgG hybridoma with a V, 
gene from the V,10 family (Table 1 and Fig. 3). In almost 
every case, at least one IgM and one IgG hybridoma expressed 
the same V. gene, usually with a different D~. Notable ex- 
ceptions were two IgM-producing hybridomas, one of which 
had a VH derived from the V~606 family and the other from 
the VH36-60 family (Table 1). These two V. gene families 
were not represented among any of the IgG-producing hy- 
bridomas. Likewise,  hybridomas expressing a V. from the 
VHSl07 family were found only among IgG-producing hy- 
bridomas (Table 1 and Fig.  2). 
The estimated number of different germline V. genes that 
could encode an anti-DNA antibody is 44 (see Materials and 
Methods). The probability that four different clones out of 
the total of 63 would express a VH derived from the same 
germline V. gene by chance alone is 0.042. These results in- 
dicate that among the total population of clones there was 
preferential  expression  of V.  genes  homologous to  the 
V.558 family genes expressed by the anti-DNA hybridomas 
MRL-DNA22 (111.185, 165.27,  165.49,  17s.83; Fig.  1 A, 
DNA22) and BWDNA7 (111-cl, 111-c2, 17p.101, 202.80, 
202.s38, 202.135, 202.61, and 165.3m, 13 hybridomas total; 
Fig. 1  A, BWDNAT) (22). There was also preferential usage 
of a V.Q52-derived V.  gene for which homologous V. 
genes have not been reported (Fig.  1 C). 
Both the IgM and IgG anti-DNA hybridoma populations 
independently demonstrated preferential V. gene expression. 
The probability that three IgM clones cut out of the total 
of 36 would express a VH derived from the same germline 
V. gene by chance is 0.020. Therefore, there was a strong 
preference among the IgM hybridomas for V. genes homol- 
ogous to genes from the V.Q52 family (four clones: 165.33, 
165.41, 165.52, and 202.17; Fig. 1 C). There was also preferen- 
tial usage of a gene from the V.558 family similar to the 
V~ gene used by the anti-DNA hybridoma BXW-DNA7 
(22) (six clones: 17p.101, 202.80,  202.s38,  202.135, 202.61, 
and  165.3m;  Fig.  1 A, BWDNA7). IgM clones 165.60, 
163.72, and 25.12m are >--92% homologous and use a V.558 
family gene homologous to the previously described V, for 
the anti-DNA hybridoma BXW-DNA16 (22). 
As stated in the previous section, most of the hybridomas 
producing IgG anti-DNA was found to be members of clones 
represented by two or more hybridomas. Of the 29 clones 
represented among the 69 IgG hybridomas, 18 were repre- 
sented by two or more hybridomas. If the analysis of preferen- 
tial V. gene usage is determined on the basis  of the fre- 
quency that a particular V. gene is used among IgG clones, 
there was preferential expression ~  <0.025) of a V~ homol- 
ogous to the V.558 Vh31 germline gene (17s-c2, 165.3, and 
74-cl; Fig. 1 A, S57[Vh31]); and the V.S107 family Vhll Table  1.  Summary  of Variable Region Structures and DNA Specificity  for Monoclonal Anti-DNA Autoantibodies 
VH 
Mouse  Clone*  Isotype  V.S  D.II  j. 
VI.  DNA binding specificity* 
VL  ~  JL  ssDNA  dsDNA  CDLP** 
17  p101  IgM  VH558  LI  2  VK-1  1  8.84  NI*  NB 
p73  IgM  V.7183  RDN  4  VK-21  1  >10  NI  <2 
p3  IgM  V.606  TP  2  VK-2  1  EB*  NI  NB 
s93m  IgM  V.7183  RGTTVY  2  VK-1  5  1.39  15%  NB 
s128  IgM  V.558  ALRQGY  2  Vr-21  2  7.43  I9  NB 
s13  IgM  V.558  SRGYYFGSSRF  1  VK-1  1  0.46  6.51  NB 
s166  IgM  V.558  GRYT  3  VK-12  4  0.31  13  NB 
s-c6(2)  IgM  V.558  g  3  VK-4  2  0.05  NI  NB 
ps-c7(3)  IgM/G2a  V.10  DdYVA  3  VK-1  2  0.40  14  NB 
s-c1(4)  IgG2b  V.558  EDyYGss  2  VK-5  5  0.05  0.12  NB 
s-c2(2)  IgG2a  V.558  RGRSVY  2  Vr-1  1  0.04  NI  NB 
s-c3(2)  IgG2a  V.558  EGWEGGPY  2  VK-1  5  0.60  5.78  1 
s-c4(3)  IgG2a  V.558  GGnYGGS  4  Vr-21  2  0.04  0.82  NB 
s-c5(3)  IgG2b  V.558  SrYgg  4  VK-1  1  0.47  1.05  NB 
s83  IgG1  V.558  GYKA  3  VK-1  2  0.58  NI  NB 
s2  IgG2a  V.7183  NLGRRTY  2  VK-32  5  7.18  NI  NB 
s5  IgG2b  V.7183  HRGSLWLRRAD  2  Vr-19  1  0.34  3.00  4 
s130  IgG1  V.7183  DLKWLRRG  1  VK-19  2  0.27  1.53  <2 
s  145  IgG2b  V.Q52  HKYYDISP  3  Vr-2  4  0.14  35 %  NB 
111  68  IgM  V.558  GVARGS  4  VK-1  1  EB  EB  NB 
185  IgM  V.558  DG  3  VK-1  1  0.36  17 %  NB 
c1(4)  IgM/G2a  V.558  GGSGYD  3  VK-8  1  0.91  0.97  NB 
c2(3)  IgG2a  V.558  GTVIGD  4  VK-2  4  0.13  NI  NB 
55  IgG2a  V.7183  NMATA  3  VK-1  2  0.25  16%  NB 
67  IgG2a  V.7183  GSI  1  Vr-unk  5  2.50  16%  4 
33  IgG2a  V.S107  ASYGSRG  1  VK-1  4  1.13  16%  <2 
163  c4(2)  IgM  V.7183  KGLRRN  4  VX-1  3  1.55  1.09  NB 
42  IgM  V.7183  RYYGTFL  2  Vr-Oxl  1  10  1.30  NB 
72  IgM  V.558  RGITTV  3  Vr-5  1  NI  1.53  334 
100  IgM  V.558  RLRWA  3  Vr-8  2  0.08  NI  NB 
c1(9)  IgG2b/G2a  V.7183  HYYGSRTY  2  VK-8  2  0.28  1.37  1.4 
c2(3)  IgG2a  V.$107  DpygRTRs  4  VK-10  1  0.6  0.62  1 
c3(2)  IgG2a  V.Q52  KGLRRAG  4  V)x-2  2  0.5  0.12  1 
47  IgG2b  V.558  GI  1  VK-9  2  0.6  0.17  NB 
165  6  IgM  NA**  NA**  NA*t  Vr-23  1  26 %  3.4  NB 
3m  IgM  V.558  DPPLRRLYY  4  VK-19  1  0.11  NI  <0.025 
5  IgM  V.558  EGCY  1  Vr-8  2  NI  NI  2 
33  IgM  VaQ52  YYYGSPLN  1  V)x-1  1  EB  NI  <0.20 
41  IgM  V.Q52  YDGYY  2  Vr**  EB  EB  NB 
52  IgM  V.Q52  YHSTAPWW  1  NA**  EB  NI  <0.25 
54  IgM  V.36-60  SGRGA  4  Vr-23  2  0.11  15 %  NB 
27  IgM  V.558  DG  3  VK-1  1  0.095  NI  NB 
45  IgM  V.558  EA  1  Vr-8  2  17 %  NI  <2 
continued 
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VH 
Mouse  Clone*  Isotype  V.s  D.II  J. 
VL  DNA binding  specificity* 
VL  I  JL  ssDNA  dsDNA  CDLP** 
60  IgM  V.558  GETTWGKGY  2  VK-23  1  NI  8.7  NB 
3  IgG1  V.558  GDLLWLRRIL  2  VK-8  5  0.14  34 %  40 
14  IgG1  V,558  RYYGREGY  2  VK-10  4  0.16  NI  NB 
49  IgG2a  V.558  RAWD  1  Vx-8  1  0.16  NI  NB 
202  9  IgM  V.Q52  YYGSS  4  Vx-8  2  8.46  29 %  NB 
17  IgM  V.Q52  YSDYYGSS  1  VR-2  2  NI  NI  NB 
33  IgM  V,,7183  SRWLLRVG  1  VK-9  4  NI  5.87  NB 
p38  IgM  V.7183  QGWDR  4  VK-21  1  3.47  NI  NB 
54  IgM  V.558  LP  1  VK-9  2  0.16  17%  NB 
61  IgM  V.558  LIYYYGSI  3  Vg-Oxl  5  0.29  NI  NB 
80  IgM  V.558  RGYYGSS  4  Vg*~  1  EB  NI  1 
s38  IgM  V.558  GGRYDL  4  Vx-1  4  0.22  NI  NB 
135  IgM  V.558  GYYGSSYS  3  Vx-8  2  1.97  NI  NB 
105  IgG2a  V.558  RYYRR  4  VK-9  2  2.23  2.12  <2 
10  c1(4)  IgG  V.558  EDrTG  2  VK-1  1  0.70  3.17  3.5 
25  12m  IgM  V.558  GRYT  3  VK-1  2  0.34  NI  NB 
74  c1(2)  IgG  V.558  EDWDGG  3  V~-5  2  0.09  0.14  1 
c2(2)  IgG  V.$107  DKGRYGA  Vg-21  1  0.5  21%  0.005 
83  c1(3)  IgG  V.7183  GGTR  3  VK-19  4  1.91  2.74  <0.05 
185  c1(9)  IgG  V.Q52  NTPLGRRY  2  VK-12  1  0.30  0.39  NB 
* The DNA binding specifidty for ssDNA and dsDNA is presented as the amount (/zg/ml) of either ssDNA or dsDNA that was required to produce 
50% of maximum binding  in the competitive ELISA. Numbers in italics represent values extrapolated from the inhibition  curve. Percentages in 
italics are the maximum percentage inhibition of binding produced by 10/~g/ml competitor. The standard deviation of triplicate wells at each compet- 
itor dilution was always <10% of the mean OD40s. For clones with multiple bybridomas, the data presented are from one representative mAb. 
NI  -  no inhibition.  EB  =  enhanced binding;  in the presence of the competitor,  binding  to the solid-phase DNA was increased. 
* Clones represented by a single hybridoma are designated with a number.  Clones with two or more members are designated by a "c" followed 
by a number.  The number of individual hybridomas isolated and analyzed from a clone is in parentheses after each clone number.  The "p" and 
"s" designations of the clones from animal 17 refer to the partial fusion from which the hybridomas were obtained (see text).  "p" refers to the 
first fusion and "s" to the second. 
S Nomenclature  according to Brodeur and Riblet  (70). 
II Amino  acid sequence for that part of CDR3 contributed  by D.. 
Nomenclature  according to Potter et al. (71). 
** CDLP binding is presented as a ratio obtained by dividing the titer of mAb supernatant that produces 50% of maximum binding to CDLP in 
the solid-phase ELISA divided by the titer that produces 50% of maximum binding to DNA in the solid-phase ELISA for DNA binding. The dilution 
of supernatant  that produced 50%  maximum binding  to solid-phase DNA was the same dilution used in each respective competitive ELISA for 
that supematant.  NB  =  no binding. 
** The cDNA sequence was not obtained. 
germline gene (163-c2,  74-c2,  and  111.33;  Fig.  1 D).  If the 
estimation  of preferential  V.  gene  usage  is  based  on  the 
number  of hybridomas  rather  than  the  number  of clones, 
preference in V. gene usage was even stronger (p <0.004). 
Seven  hybridomas  expressed  a  V.  homologous  to  V.558- 
BWDNA7  (111-cl and 111-c2;  Fig.  1 A, BWDNA 7). 9-12 
hybridomas  expressed  a  V.  homologous  to V.Q52-165.33 
(185-cl,  17s.145,  and  163-c3;  Fig.  1 C); and  12 hybridomas 
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expressed a  V. homologous  to V.7183-Vh283  (163-cl  and 
83-cl;  Fig.  1 B,  Vh283).  The latter  estimate  assumes that 
the precursors to individual hybridomas are selected indepen- 
dently by antibody receptor-mediated events regardless of the 
size of the clone of which the respective hybridomas might 
be members. Although  the V.558  family V. gene expressed 
by the anti-DYA hybridoma 3H9 (Fig.  1 A, 2F213H9]) was 
not preferentially expressed among the hybridomas analyzed A)  vh558 
1  i0  20  3~  ~0  ~0  abc  ~0  I0  ~0  ~0 
SWDNAI6  EIQLQQSGAELVKPGASVKISCKASGYSFT  GYN~{WVKQSHGKSLEWIG  NINP  YYGSTSYNQKFKG  KATLTVDKSSSTAYMQLNSLTSEDSAVYYCAR 
165.14  ...............................  i .................................................................  RYYGREGY 
17s.128  ...............  x ...................  ,---L  ................  IT .........................................  ALRQGY 
17s-cl  -V ......  P ..........  M .......  T--  D-Y--I  ..............  R---  SN-G  ..................  L ......................  EDYYGSS 
165.60  -V ......  P ..........  M .......  T--  D-Y--I  ..............  RV--  SN-G  ..................  L ......................  GETTVVGKGY 
163.72  -V ......  P ......  D---M  .......  T -~  D-Y-DI  ..............  Y-Y-  NN-G  ........................  E-H  ..............  RGITTV  --- 
25.12m  QV .....  DR ......  x ...........  T--  D---DI  ..............  Y-Y-  NN-G-G  ......  S  ...............  E-H  ..............  GRYT  -A- 
10-cl  -V ......  P .......................  YVHI  .....  PE ....  SL-  E---  RT-G-T  ......  A  .................  K ............  T-  EDRTG  .... 
17s.166  -V ......  P ......  x ................  Y-H]  .....  PE .......  E---  ST-G[T  ......  A  .................  K ..............  GRYT  -A- 
2F2  QVQLQQSGPELVKPGASVKISCKASGYAFS  SSWMNIWVKQRPGKGLEWIC  RIYP  GDGDTNYNGKFKD  KATLTADKSSSTAYMQLSSLTSEDSAVYFCAR 
17s-c4  ...........................  E--  R ....  l ....  G .........  W ....... IK ......  G  R ..............  H .......  G .......  K  GGNYGGS  FYALDY 
17s.13  .......................  T ...........  l ..............  W-x-  R ...................  I--N  ..............  T ......  SRGYYFGSSRF  F-V 
DNA22  QVQLQQPGAELVKPGASVKLSCKASGYTF~  SYWINIWVKQRPGQGLEWIG  NIYP  GSSSTNYNEKFKS  KATLTVDTSSSTAYMQLSSLTSDDSAVYYCAR 
111.185  ...................................  i ................................................................  DG 
165.27  .............  xxx  ...................  i ................................................................  DG 
1~5.~  .......................  ZX~[Z~ZZZZZ~  ..................................................  "~ 
17s.83  ....................................  II-HF  .....  N  ...............................  G  GYKA 
163.100  .................................  MH I ..............  E-N-  SNGG  ......... 
17s-c6  ................................  M ........  l  R ......  R-H-  SD-E-H--Q  .... 
163.47  .............................  N--M-I  .......  R ......  R-L-  SDTE-H--Q---N 
17S-C3  ......  S ....  AR .........  R .......  N-D--I--R--A  ........  E---  R-GNIY  ......  G 
BWDNA7  VKMSCKASGYTF~  SYVMHIWVKQKPGQGLEWIG  YINP  YNDGTNYNEKFKG 
lll-cl  EVQLQQSGPELVKPGAS  ..................  ' .......................  K ....... 
iii-c2  .............................  R ....  i ........................  K ....... 
17D.101  ...............  VX .................  l ........................  K ....... 
202.80  ...................................  i ........................  K ....... 
202.$38  ...................................  i ........................  K ....... 
202.135  ...................................  i ........................  K ....... 
202.61  ...................................  ' ........................  K ....... 
165.3m  ................  ' ........................  K ....... 
$57(Vh31)  KPGASVKISCKASGYTF~  DYYINIWVKQRPGQGLEWIG  WIYS 
17s-c2  QIQLQQSGPELVR  .....................  ' .................  P 
165.3  ............  R .....................  ' .................  P 
74-ci  Q-R  .........  R--x  ...................  , .................  P 
202.105  EV ...............................  MHI  ....  K .........  E--P 
111.68  -V .................  L ............  T-HI  ....  S ............  P 
165.45  -V .................  L ............  T-~i  ....  $ ............  p 
17s-c5  QVQLQQSEAELARPGASVKMSCKASGYTFI  RYWMHI  WVKQRPGQALENIG 
165.5  ............  ~ZZI  ........  ~ ..... 
202.54  ....... ~  .... ~  .............. ~  .......... ~  ..... 
YAY 
WYFDV 
WFV- 
.......  K ..............  E .......  TI  RLRWA  WF-- 
.......  K--T---I  .................  R  F-- 
.......  K-T  ....  IR ......  E--GI  .....  GI  YWYFDV 
.....  A-K  ....  T--H--G---G  .........  EGWEGGPY  YFD- 
KATLSSDKSSSTAYMELSSLTSEDSAVYYCAR 
....  T ...........................  GGSGYD  GFAY 
....  T ...........................  GTVIGD  YYAMD- 
....  T ..........................  S  LI  Y-D- 
....  T ...........................  RGYYGSS  YAMD- 
....  T ...........................  GGRYDL  YYAMD- 
....  T ...........................  GYYGSSYS  W--- 
....  T ...........................  LIYYYGSI  --- 
....  T ...........................  DPPLRRLYY  YAMD- 
GSGNTKYNEKFKD  KATLTVDTSSSTAYMQLSSLTSEDSAVYFCAR 
............  G  ................................  RGRSVY  YFDY 
........................................  RYYRR  SYAM-- 
........  D---~  ---M-A-K  ........................  GVARGS  AM-- 
........  D---~  ---M-A-K--R  .....................  EA  YW---V 
SRYRG  YSMDY 
EGCY  YWYFDV 
LP  WYF-V 
AIYP  GNSDTNYNQKFK(  KAKLTAVTSASTAYMELSSLASEDSAVYYCAR 
.........  S ...........................  TN ........  T- 
Y-N-  SSGY-E  ......  D  --T---DK-S  .....  Q ....  T ..........  S 
102 
YFDY  W 
W 
W 
W 
W 
B)  Vh7183 
1  i0  20  3~  ~0  ~0  abc  fi0 
Vh283  EVMLVESGGGLVKPGGSLKLSCAASGFTFS  SYTMS  WVRQTPEKRLEWVA  TISS  GGGNTYYPDSVKG 
202.33  ....  A ......................  G ...................  G  .........  T--- 
163-ci  --K  .............................  A ........  A .......  Y ...... S ......... 
83-ci  --K-M  ...........................  V ........  A .......  Y ..... DS .....  NM-- 
17S.5  .........  A ....................  D-A  ........  Q .............  IY .....  G-Q- 
17s.93  --Q  ......  A ....................  N-A  .......................  SY ......... 
202.38m  --Q  .............................  A ................  A-N-  N--S  .....  T--D 
17D_73  EVQLQQSGAELVRPGASVKLSCTASGFNIK 
111.67  .............................. 
17S.2  EVQLVESGGGLVKPGGSRKLSCAASGFTFS 
111.55  .............................. 
163.42  ......................  Y-M  .............  1- 
163-c4  ........................  M-  .............. 
DNA13  EVKLVESEGGLVQPGSSMKLSCTVFGFSFS  DYYMA  WVRQFPEKGLEWVA 
17S.130  .......................  AS--T  ...........  V ......... 
C)  VhQ52 
165.33  QVQMKESGPDLVQPSQTLSLTCTVSGFSLS  SYGVK  WFRKppRKGLEWLG 
DDYMH  WVKQRPEQGLEWIG  RIDP  ANGNTKYAPKFQD  KATITADTSSNTAYLQLSSLTSEDTAVYYCAR  RDN 
---L  ..................................................................  GSI 
DFGIH  WVRQAPEKGLEWVA  YISR  GSGTIYyADTVKG 
-Y-M  ..................  S  --FN  ......... 
---G  --N  .......... 
---S  --S  .......... 
KINY  DGSNTYYLDSLKG 
N ...... S-H  ....... 
GIW  SGGSIYYTPALSS 
I0  ~0  ~0  102 
RFTISRDNAKNNVYLQMSSLRSEDTALYYCAR 
...........  TL ...................  SRWLLRVG  YWYFDV 
...........  TL .............  M ....  S  HYYGSRTY  ---Y 
...........  TL .............  M .....  GGT  R-AY 
-L .......  R-TL  .............  M .....  HRGSLWLRRAD  ---Y 
---x  .......  TL ...................  RGTTVY  ---Y 
...........  TL ...................  QGWDR  AM-Y 
RFTISRDNDKNILFLQMTSLRSEDTAIYYCAR  NLG~TY 
........  A--T  ..............  M .....  N~TA 
....  F---A--T  ..............  M .....  IRYYGTFL 
........  A--T  ..............  M .....  !KGL~ 
RFIISRDNAKNILYLQMSSLKSEDTATYFCSR  VNYNGI~  CFAD 
........  G ...................  Y-T-  DLKWL~G  YWY-DV 
YYYGSPLN  WYFDV  RLSVSRDISKSQVFFKMSSLQSEDTAVYHCA~ 
165.41  ---M  ...........  x ............  x ......................................................................  YDGYY 
165.52  ...........................................................................................  YHSTAPWW 
202  .  17  ---MQ  ......................... 
202  .  9  ---L  .........................  T 
185-ci  ---L  .....  G--A---S--I  .........  T 
17S  .145  ---L  .....  V--A---S--I  .........  T 
163-c3  ---L-Q---G  ......  S--I  .........  T 
D)  ~rnS  107 
Vhll  EVKLVESGGGLVQPGGSLSLSCAASGFTST 
163-c2  --N  .........................  F- 
74-c2  ...............  x ............  F- 
111.33  ............................  F- 
---y 
.....................................................................  YSDYYGSS  Y ..... 
......  V-Q--G  .....  V-  TMG  W-DKK--NS--K  ....  I---T--N---L-L  ....  T ....  M-Y-TY  YYGSS  YYAM-Y 
--AIS  -V-Q--G  .......  V--  T--DTS-NS--K  ....  I-K-N  ......  L--N---TD---R-Y---  NTPLGR~RY  ---Y 
--G-H  -V-Q--G  .......  V--  A---TN-NST-M  ....  I-K-N  ......  L--N---AD---MFY-VK  HKYYDISP  -AF 
N-G-H  -V-QS-G  .......  M ..... NTD-NA-FI  ....  I-K-N  .........  N---AD---I-F---  KGL~G  AM-Y 
DYYMS  WVRQPPGKALEWL~  LIRNKANGYTTEYSASVKC  RFTYSRDNSQSILYLQMNALRAEDSATYYCAR 
....  N  .....................................  I ..............  V--T  ..........  DPYGRTBS  YTMDY 
......................  K---D  ..............  I---D  ........................  DKGRYGA  WFA- 
Y ...............  C ........................  L ..........................  T-  ASYGSRG  WYF-V 
W 
YYAMDY  W 
WYF  -V  - 
YFDY  W 
W-V-  - 
Y YAM-  D  - 
W 
W 
W 
f.laat.S~ 
Cloa~  Sl~ 
Figure  1.  Translated amino acid sequences for VH (one-letter  code).  The sequences are grouped  according  to the V. family from which each VH 
was derived. Within the VH grouping, sequences are ordered according  to homology with the reference sequence. Dashes  indicate identity with the 
reference sequence;  blanks indicate  either  that  the VH does  not have an amino acid at that position or sequence was not obtained  for that region. 
766  Clonally Sdective Stimulation of IgM and IgG Anti-DNA in this study, this V~ gene was found to be preferentially ex- 
pressed among anti-DNA hybridomas from MLR lpr/ipr  mice 
(9). There was no apparent preferential  expression of a par- 
ticular J~ or V~-J~ combination among either IgM or IgG 
hybridomas. 
Arginines in VH CDR3 Derived by Unusual DH Recombi- 
nation.  More than 50% of the clones, 35 of 63, had a VH 
with one or more arginines in CDR3 (Table 1 and Fig.  1). 
This is a highly characteristic feature of anti-DNA antibodies 
in mice (6, 7, 9, 22-29) and humans (30, 31). This region 
of the heavy chain is formed by recombination of one or more 
D~ genes within the 5' end of a J~ gene and the 3' end of 
a VH gene (32, 33).  Arginines are generally rare in CDR3 
(9) and are the products of random events in the recombina- 
tion process (24). As we have demonstrated previously (7), 
arginines in VH CDR3 can be generated by several different 
mechanisms. These include N  sequence addition (34,  35), 
such as in 17p.73,  17s.93m,  163.100, and 202.105.  A shift 
from the normal reading frame, RF1 (36, 37), of a DFL16 or 
Dsp2 gene  to  a  different  reading  frame,  RF3,  can  also 
generate arginines in VH CDR3.  This frame shift can be 
caused either by N sequence addition, such as in 163.100 and 
165.3  or DH-D~ recombination (33)  or inversion  of a Da 
gene during recombination, such as in 17s.13. AU these mech- 
anisms for D region diversity have also been reported by others 
(9,  24, 38--40). 
Selected V~ Gene Expression among Both IgM and IgG H~ 
bridomas.  V~ from each of the V~I, V~2, V~4, V~5, V~8, 
V~9, VA0, V~12, V~19, V~20, V~21, and V~23 gene fami- 
lies and from the V~Ox-1, V~RF, Vxl, and Vx2 germline 
VL genes were expressed among the hybridomas analyzed in 
this study (Fig. 2). The estimated number of different germ- 
line V~ genes that could be used to generate an anti-DNA 
antibody is 62 (see Materials and Methods). Based upon this 
number of V~ genes, the probability that three clones would 
express the same V~ gene is <0.018.  Therefore, there was 
preferential usage of a V~ gene derived from each of the V~2 
and V~5 germline families. The preferentially used V~2 gene 
was 92% homologous to the V~2 gene expressed by the pre- 
viously identified anti-DNA hybridoma BXW-DNA14 (17p.3, 
111-c2, and 17s.145; Fig. 2 C) (22). The preferentially used 
V~5 gene was 92% homologous to the V~5 gene expressed 
by the anti-DNA hybridoma MRDDNA22 (163.72, 17s-cl, 
and 74-cl; Fig. 2 D) (22). Preference for V~ derived from the 
VA and V~8 families was much stronger (p g0.000080) for 
seven or more clones expressing the same (95% homologous) 
VA or V~8 gene. The V~I genes expressed by all the clones 
in Fig. 2 A  are ~>91% homologous to the V~I expressed by 
the previously reported anti-DNA hybridoma MRDDNA4 
(22). Most of the clones expressing a V~ gene from the V~8 
group expressed a V,8 gene ~98% homologous to the V~ 
gene expressed by the anti-DNA hybridoma DNA5 from 
done 4 (7). 
The preference for VA and V~8 was apparent among both 
IgM and IgG hybridomas ~  g0.0027 and p <0.00013, respec- 
tively). Among the IgM dories, five clones (17s.93m, 17p.101, 
25.12,  111.185, and 165.27; Fig. 2 A) each expressed a VL 
derived from the same V,1 gene, and three clones (202.9, 
165.45, 111-cl, and 165.5; Fig. 2 B) each expressed a VL de- 
rived from the same V,8 germline gene. Among IgG clones, 
four expressed  a VL derived from the same VA germline 
gene (17s-c2, 17s-c3, 17s-c5, and 17s.13; Fig. 2 A), and four 
expressed  a VL derived from the same V~8 germline gene 
(165.49,  163-cl,  111-cl, and 165.3; Fig. 2 B). These results 
indicate preferential  clonal selection and expansion of anti- 
DNA B cells expressing either V~I or V~8 during both the 
early IgM and late IgG anti-DNA response in the autoim- 
mune mice from which our panel of hybridomas was obtained. 
JJ Junctional Diversity among VL of Anti-DNA  Hybrid- 
omas.  Assuming that each J~ has an equal probability for 
expression among anti-DNA B  call clones, J~l  was over- 
represented and JA and J~5 were underrepresented among 
the clones listed in Table 1 (p <0.025).  This unequal represen- 
tation of J~l is consistent with normal J, usage in mice (41). 
However, 8 of the 23 JA clones had arginine (CGG) as the 
first codon encoded by J,1 instead of the germline trypto- 
phan (TGG).  This position would correspond to position 
number 96 in VL CDR3, according to the numbering con- 
vention of Kabat  et al.  (42).  This conversion would most 
likely occur from junctional diversity between V, and J, (43) 
but could also be due to somatic mutation. 17 hybridomas 
from eight  clones  expressed  the  altered  JA  (IgM  clones 
111.185, 17p.3, and 163.72; and IgG clones 10-cl, 111-cl, 163- 
c2,  17s.5, and 74-c2).  Each of the IgG clones had two to 
nine members, indicating that B cells with VL derived from 
JA with the tryptophan-~arginine conversion may have been 
selectively expanded. 
Selection for  V~,558-Vj and  VH558-V~8.  Assuming an 
equal probability for any of the possible anti-DNA VH genes 
to be expressed with any of the possible V~ genes in a given 
B cell, significantly more clones expressed VH-V~ combina- 
tions generated from a VH558 family V. and either a VA or 
V,8 family V~ than would have been expected if VH and VL 
genes assorted  randomly (p <0.0018 for V~558-VA, and p 
<0.029 for V~558-V,8). When the data were analyzed to de- 
termine ff a particular VH gene-V~ gene combination was ex- 
pressed at a higher-than-expected frequency among the clones, 
one combination was found to be preferentially used. The 
IgG hybridoma 17.s83 and the IgM hybridomas 111.185 and 
165.27 expressed nearly identical V~ and VL genes. The VH 
gene was similar (~93% homology) to the V~558 family V~ 
gene previously reported for the anti-DNA hybridoma BXW- 
An "x" indicates  sequence  ambiguity  for the relevant  position.  The sequences  are numbered  according  to Kabat et al. (42); CDR regions  are enclosed 
within rectangular  boxes. The clone numbers  of IgM-producing  hybridomas  are underlined.  The nucleotide  sequences  from which these translated 
sequences were derived  have been submitted  to the EMBL/GenBank  Sequences  Libraries. The origin of the reference  sequences  are (A) the VH558 
family VH genes  for the anti-DNA hybridomas  BXW-DNA16, MRL-DNA22, and BXW-DNA7 (22) and the V~ for the anti-DNA hybridomas  2F2 
and $57 (Vh31) (9); (B) the VH7183 family  germline  gene Vh283 (9, 72) and the anti-DNA hybridoma  DNA13 (7); (D) the V~$107 family  germline 
gene Vhll (73). 
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MRLDNA4 
17s-c2 
17s-c3 
17s-c5 
17s.93 
17S.13 
l  i0  20  30  I0  ~0  ~0  ZO  ~0  ~0 
DVVMTQIPLSLPVSLGDQASISC  RSSQSLVHS  NGNTYLH  WYLQKPGQSPKLLIY  KVSNRFS  GVPDRFSGSGSGTDFTLKISRVEAEDLGVYFC  SQSTHVPYT 
......  T ..............................................................................................  W- 
......  T ...............................................................................................  L- 
......  T ..............................................................................................  W- 
......  T ...............................................................................................  L- 
......  T ........................  N  ................................................................  C ....  W- 
17D.101  ......  T ................ 
111.55  ...........  T ........... 
........  N  ......  D 
........  N  ......  Y 
...............  RX ..................................... 
...............  R ...................................... 
25.12  ......................................  Y  ............... 
111.185  ......  T ..............................................  Y 
17s.83  2;2~  ~2~ 
202.s38  ......  T ................  [  .....  I .........  E  ............... 
J 
111.68  ......  T ................  I  .....  I .........  E  ............... 
I 
111.33  --L---T  ................  I  .....  I-NR  ......  E  ............... 
10-cl  ..................  V ....  [  ........  D  --D---Y  ............... 
B) v~  I  0 
DNA5  DIVMSQSPSSLAVSAGEKVTMSCKSSQSLLNSRTRKNYLA  WYOQKPGQSPKLLIY 
202.9  ......................................................... 
165.45  ......................................................... 
165.49  .....................  --I ................................. 
163-CI  ......................................................... 
lll-cl  ....................... 
165.3  ....................... 
165.5  ....................... 
163.100  ....  T .......  M-V-Q  ...... 
202.135  N-M-T  .................. 
C) V~ 
BWDNAI4 DVVMTQTPLTLSVTIGQPASISC 
17D.3  ....................... 
iii-c2  .........  S ............. 
17s.145  .........  S ............. 
D) VK4/$ 
DNA22  QIVLTQSPAIMSASLGERVTMTC  ~ASSS 
163.72  ..............  L ............ 
17s-cl  ..............  L ............ 
74-ci  ....  I .........  L ........  ~  .... 
17S-C6  ..............  P--K--L  ....... 
E) Vr9 
Vk-41  DIQMTQSPSSLSASLGERVSLTC  RASQ 
202.105  ............................ 
Vk9.42  DIQMTQSPSSLSASLGGKVTITC  KASQ 
202.33  ............................ 
202.54  ............................ 
DNAI3  DIKMTQSPSPMYASLGERVTITC  KASQ 
163.47  .........  S .....  E ........... 
.......  K ......... 
........  R ........ 
R ...................................... 
R ...... 
R ...... 
RT ..... 
R ...... 
.....................................  y- 
.....................................  y- 
.....................................  y- 
............................  L .......... 
WASTRES  GVPDRFTGSGSGTDFT  LT I S SVQAEDLAVYYC 
F-G  ....  Q- 
L-G  ....  F- 
L-G  ...... 
F-G--I-R- 
FxG  ....  W- 
F-G  ...... 
L-V  ....  Y- 
F-GS---F- 
F-GS---W- 
F-GS-x-F- 
! --G-Y--R- 
I 
KQSYNL  RT 
...........................................  H- 
.............................................  y- 
............................................  x  W- 
.............................................  y- 
..................................................  I ........... 
............................................................  L- 
--M .............................. 
.........  SNQ ..... 
.....  V-Y-SNQ  ..... 
KSSQSLLDS  DGKTYLN 
.......  H-N  ...... 
.......  H-N  ...... 
......  H ....... 
VSSSYL) 
..............  V 
WLLQRPGQSPKRLIY 
...........  L--- 
...........  L--- 
...........  L--- 
WYQQKPGSSPKLWIY 
......  H ................ 
-R ....  H  ............... 
-R ....  H  ............... 
.............................................  y- 
F ............  I .....................  D-F-  Q-H-STPY- 
.......................................  H-YLSS  Y- 
LVSKLES  G IPDRFTGSGSGTDFTLK  I SRVEAEDLGVYYC  WQGTHFPRT 
-V  ....  S .........................  L-A  ...... 
......  S ................  V ........  L-H  ....  F- 
......  S ................  V ........  L-H--C-x- 
STSNLAS  GVPARFSGSGSGTSYSLTISSMEAJ~DAATYYC  QQYSGYPFT 
.......................................  H--HRS-R- 
.......  H--HRS-L- 
......................  A ....  N ...........  H-DHRS-P- 
.....  LY  ...............  X ..................................  S-FC  H-W-S--Y- 
DIGSSLN  WLQQEPDGTIKRLIY  ATSSLDS  GVPKRFSGSRSGSDYSLTISSLESEDFVDYYC  LQYASSP 
E-SGY-S  ....  K ..........  S--T-N  ............................  A ...........  YT 
DINKYIA  WYQHKPGKGPRLLIH  YTSTLQP  GIPSRFSGSGSGRDYSFSISNLEPEDIATYYC  LQYDNL 
--X ........................................  x ......................  x  F- 
....................................................................  y- 
DINNYLS  WFQQKPGKSPKTLIY  RADRLVD  GVPSRFSGSGSGQDYSLTISSLEYEDMGIYYC  LQYDEFPYT 
...........  I ............  K .....................................  H ..... 
Figure 2.  Translated amino acid sequences for VL. The organization  of the sequences is as in Fig.  1 according to the V~ subgroups as defined by 
Potter et al. (71) and numbering according to Kabat et al. (42).  The nucleotide  sequences from which these translated sequences were derived have 
been submitted  to the EMBL/GertBank Sequences Libraries. The sources of the reference sequences are (.4, C, and D), respectively, V~ from anti- 
DNA mAbs MR.L-DNA4,  BXW-DNA14, and MRI-DNA22 (22); (/3 and E), respectively, V~ genes from the anti-DNA mAbs DNA5 and DNAD 
DNA22 (Fig. 1 A, BWDNA22) (22). The V~ gene was the 
same (>198% homology)  VK1  family  gene  previously  re- 
ported for MRI:DNA4 (Fig. 2 A, MRLDNA4). The prob- 
ability  that  this  V.-VL combination  would have appeared 
three times by chance among the 63 clones is <0.0002. These 
results are even more striking since each of the three clones 
that express the V.558-BWDNA22-VA-MRLDNA4  com- 
bination  was  obtained from  a different animal. Moreover, 
111.185 and 165.27 are nearly identical in both VH and VL, 
including  the D.-encoded VH CDK3.  These  two hybrid- 
omas  differed in  their V.  and VL sequences by only  two 
identifiable amino acids at positions 94 and 96 in VL CDK3 
(Fig. 2 A). The difference in position  96 between the two 
VL sequences is due to the JA difference discussed above. 
165.27 has the germline tryptophan at this position,  while 
111.185 has arginine. 
IgM and IgG Anti-DNA Are Structurally  Similar.  The data 
in Table 1 and Figs. 1 and 2 indicate that the IgM and IgG 
populations are completely overlapping with respect to VH 
and VL structure. The clones  17s.83, 111.185, and 165.27 
described above demonstrate particularly well the similarity in 
structure between IgM and IgG anti-DNA.  In two clones 
from two different mice, both IgM and IgG hybridomas were 
obtained from the same clone (Fig.  3). The 17ps-c7 clone 
is particularly interesting. The hybridomas from this mouse 
are divided into p and s groups. The p group was generated 
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(7); (E) the V,9 germline gene vk41 (74) and V~ 9.42 from hybridoma 15-56-1 (75); (F) V~ from the NC6-C8 hybridoma (76); (G) the VA2 germline 
gene k2 (77); (H and]), ~*spectively, V, from the AM17-26 and AM15 rheumatoid factor hybridomas (49); (/) V~ from the anti-DNA hybridoma 
C8.5 (58); (I) the germline V,21E gene (78); (K) V~ from the anti-DNA hybridoma Dp12 (9); (L) V~ from the rheumatoid factor hybridoma MR.b 
RF24 (79); (M) V~ from the antidextran hybridoma 45.21.1  (80); and (N) the germline Vxl (81) and Vx2 genes (82). 
from a partial splenectomy of this mouse at the age of 24 
wk, when the mouse's serum IgM anti-DNA titer was 1,800 
and IgG anti-DNA titer <90. Five IgM anti-DNA hybrid- 
omas out of a total  of five were analyzed  from this fusion 
(Table 1). The remaining half of the spleen was removed 1.5 
mo later when the mouse's serum IgG anti-DNA titer was 
>2,400.  Six IgM and 20 IgG hybridomas out of a total of 
94 were analyzed from this fusion. The IgG hybridoma 17s.161 
derived from the second fusion was found to be clonally related 
to IgM hybridomas 17p.79 and 17p.80 obtained from the first 
fusion (Fig. 3 A). Clonality of these hybridomas was confirmed 
by identity of both productive and nonproductive J. and J, 
rearrangements (21) (not shown). The IgM hybridoma 111.19 
and the IgG hybridomas 111.61, 111.100, and 111.109 from 
clone 111-cl were also found to be clonaUy related, although 
these hybridomas were all generated in the same fusion (Fig. 
3 B). Somatic mutations were apparent in both clones. The 
effects of these mutations on specificity for DNA will be dis- 
cussed elsewhere (Jou et al., manuscript in preparation). These 
results indicate that some, if not all, of the secondary, IgG 
anti-DNA antibodies are generated by selective clonal expan- 
sion of B cells  that are initially stimulated to generate  the 
primary IgM anti-DNA antibodies in autoimmune (NZB  x 
NZW)Fi  mice. 
Structural Basis  for ssDNA vs. dsDNA Specificity and Selec- 
tion for dsDNA Specificity among Clonally Expanded B Cells. 
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VII  G~uVa~G~nLeuVa~G1uThrG~yG~yG~yLeuVa~G1nPr~Ly~G~ySerLeuLysLeu~erCysPr~A~aserG~yPheSerPheAsn~ThrAsnA~aMetAs"~Tr~Va~G  VhlO  GAGGTG~AGCTTGTTGAGACT~GTGGAGGATTGGTGCAGC~TAAAGGGTCATTGA~ACTCTCATGTCCAGC~TCTGGATT~AG~TTCAAT  ACCAATGCCATGAAC  TGGGTC 
P17.79  .............................................................................................................. 
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317.161  ..................................................................  G  ..........................  GC  ................ 
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Figure 3.  VII and VL cDNA se- 
quences  for  the  mAbs  from  (A) 
clone 17ps-c7 and (B) done 111-cl. 
The reference sequences are (A) for 
V.,  Vhl0 (83),  and for VL, the V~ 
from MRL-DNA4 (22); and (/3) for 
V.,  V.  from  BXW-DNA7  (22), 
and  for  VL,  V~ from  DNA5  (7). 
Dashes indicate identity of nucleo- 
tides with the reference sequences. 
CDR regions  are enclosed within 
boxes.  The  Ig  H  isotype  of  the 
respective mAb is indicated. Num- 
bering is by sequential nucleotides. 
The  mAb  produced  by  each  hybridoma  was  assayed for 
specificity  of binding to ssDNA,  dsDNA,  and cardiolipin 
(CDLP) t (Table 1). Although all the mAbs bound to DNA 
in a direct ELISA (Materials and Methods), a small number 
(8 IgM mAbs out of 107 total mAbs) were not competitively 
inhibited by either ssDNA  or dsDNA  in the competitive 
ELISA. This may be a reflection of the higher avidity of these 
antibodies  for binding to immobilized DNA. In fact, six of 
770  Clonally Selective  Stimulation of IgM  and IgG Anti-DNA the IgM mAbs (17p.3, 111.68, 165.33,  165.41, 165.52, and 
202.80) that were not competitively inhibited demonstrated 
increased binding to the solid-phase  DNA in the presence 
of competitor DNA (Table 1). The most likely explanation 
for this observation is that these antibodies have relatively 
low affinity for binding to DNA. In the presence of compet- 
itor and because of the high avidity of IgM, the antibodies 
are able to form a lattice that stabilizes their binding to the 
immobilized DNA. There was no significant relationship be- 
tween particular V, or VL gene expression by different hy- 
bridomas and the absolute ability of the antibodies from those 
clones to bind to ssDNA vs. dsDNA or CDLP (0.05 <p 
<0.10). Likewise, there was no correlation between arginines 
in VH CDR3 and specificity for DNA among the antibodies. 
However, as discussed below, the position of argipines in VH 
CDR3 had a remarkable effect on the DNA specificity of 
the respective  mAb; and particular VH and VL structural 
combinations  also  had  demonstrable  effects  on  DNA 
specificity. 
All of the mAbs that had an argipine at position 96 in 
VL bound to dsDNA. As indicated above, arginine at this 
position was most likely derived from junctional diversity 
in V~ to J~l recombination. The recurrent nature of this ran- 
domly generated structure among clones using J~l suggests 
that this structure may have been specifically selected. This 
possibility is supported by results from a comparison of mAbs 
111.185 and 165.27. Although both mAbs bind to ssDNA 
very well (Table 1), 111.185 binds poorly but measurably and 
consistently to dsDNA. These two antibodies differ in VH 
and VL at only two identifiable positions. 111.185 has an isoleu- 
cine instead of valine at position 94 in VL CDR3. More im- 
portantly, 111.185 has an arginine instead of tryptophan at 
position 96 in VL CDR3. 
There was a very interesting and highly significant trend 
relative to the specificity of antibodies produced by IgM vs. 
IgG clones. A significantly higher percentage of IgG clones 
produced antibody that bound to both ss- and dsDNA or 
dsDNA alone as opposed to ssDNA binding alone (Table 
1). Of 27 IgG clones, 21 had one or more hybridomas that 
produced anti-dsDNA antibody, compared with 12 of 34 IgM 
clones (p <0.001). This difference was even more pronounced 
when individual hybridomas rather than clones were com- 
pared (p <0.0005).  The difference in dsDNA binding between 
IgM and IgG mAbs was also observed within a single done, 
17ps-c7. The IgM mAbs 17p.79 and 17p.80 both bound to 
ssDNA with relatively  high avidity but did not bind to 
dsDNA 0ou et al., manuscript in preparation). The IgG mAb 
from the donally related hybridoma 17s.161, obtained 1.5 mo 
later, bound to ssDNA and dsDNA. 
Discussion 
The results from our analyses of the hybridomas described 
above confirm our previously reported results that the IgG 
anti-DNA hybridomas from an individual (NZB x  NZW)- 
F1 mouse were oligodonal and somatically mutated (6, 7), 
and therefore had the characteristics  of secondary immune 
antibodies (21, 44-48). The present results indicate that the 
oligoclonality of IgG anti-DNA hybridomas observed previ- 
ously was not unique to a single mouse and may, in fact, 
be a general characteristic of IgG anti-DNA hybridomas ob- 
tained  from  individual  (NZB  x  NZW)F1  mice.  These 
results corroborate the hypothesis that the spontaneous IgG 
anti-DNA antibody response characteristic  of these mice is 
generated as a donally selective, Ig receptor-specific immune 
response. IgG anti-DNA hybridomas from MRL lpr/Ipr mice 
are also oligodonal and the mAbs from those hybridomas 
are characteristic of secondary immune antibodies (8, 9, 25). 
Oligodonality of IgG anti-DNA antibodies has also been 
observed among anti-DNA mAbs from autoimmune (NZB 
x  SWIL)F1 mice (27) and among V,11 encoded anti-DNA 
in (NZB  x  NZW)F1 mice (28). 
The IgM anti-DNA hybridomas from the mice in this study 
also appear to have been derived from B cells that were stimu- 
lated in a donally sdective, antigen-specific manner. This con- 
clusion is based on the statistical analyses of V, and VL gene 
expression among the IgM clones. Even though each of the 
44 V~ and 62 VL germline genes in the estimated anti-DNA 
V gene repertoire could encode an anti-DNA antibody, two 
V, and two V~ genes were each expressed in a much larger 
number of IgM hybridomas than would have been expected 
in the absence of antibody receptor-mediated selection. The 
preferential V gene expression among IgM hybridomas was 
not the end result of the process by which hybridomas were 
chosen for doping since the only criterion used was the ability 
of the antibody in the respective fusion well to bind DNA. 
Based upon the results from the competitive ELISA used to 
test the specificity of each mAb (Table 1), the selection of 
hybridomas for doping was not biased with respect to the 
specificity or at~nity of the respective mAbs. As the results 
in Table I clearly demonstrate, hybridomas producing both 
high- and low-at~pity mAb were represented in our sample. 
We (4) and others (49) have demonstrated that the hybrid- 
omas obtained from autoimmune mice are representative  of 
the serum antibody in the fusion donor. 
This report provides the first demonstration that both IgM 
and IgG anti-DNA antibodies within individual autoimmune 
mice may be derived from the same B cell clones. The results 
demonstrate that the V regions of IgM and IgG anti-DNA 
antibody in autoimmune (NZB  x  NZW)F1 mice are struc- 
turally similar. Also, the V~ and VL genes that were prefer- 
entially expressed among the IgM anti-DNA hybridomas were 
also  preferentially  expressed  among the IgG hybridomas. 
Within individual mice, both IgM and IgG anti-DNA anti- 
bodies may be produced by donally related B cells. There- 
fore, B cells that are selectively stimulated to produce the 
IgM anti-DNA seen early in autoimmune (NZB  x  NZW)F1 
mice may differentiate  and clonally expand to generate the 
IgG anti-DNA seen later in the same mice. In addition, the 
results  demonstrate that  there was  greater  specificity  for 
dsDNA binding among the IgG mAbs than the IgM. This 
may indicate preferential  selection for  dsDNA  specificity 
among B cell clones that are stimulated to expand and differen- 
tiate to IgG production. The results suggest that the stimulus 
771  Tillman  et al. for this B cell clonal expansion may be native DNA.  The 
results are also consistent with and may explain the observed 
progression of anti-DNA autoantibody in both mouse and 
human lupus from more ssDNA-specific to more dsDNA- 
specific antibody (1, 3). Taki et al. (50) have likewise isolated 
an IgM hybridoma from an (NZB  x  NZW)F1 mouse that 
may be clonally related to an IgG hybridoma from the same 
mouse. The IgG mAb had much higher avidity for dsDNA 
than the IgM mAb. The VH used by both hybridomas was 
the same, and H  chain rearrangements in the two hybrid- 
omas were the same. However, since the authors did not ana- 
lyze the respective hybridomas for either L chain sequences 
or rearrangements, the clonal relatedness of the two hybrid- 
omas cannot be assured. 
Results from previous studies of B cell activity and anti- 
body production in autoimmune (NZB  x  NZW)F1 mice 
led to the hypothesis that anti-DNA antibody was a byproduct 
of polyclonal B cell activation (reviewed in reference 14). In 
light of the results from analyses of the effect of the host 
environment in which B cells develop on the ontogeny of 
anti-DNA autoantibody (15, 51) and the clonotypic analyses 
of IgG anti-DNA antibodies in autoimmune mice (6, 8), this 
hypothesis has recently been modified to propose that the 
early, IgM anti-DNA B cells are polyclonally activated and 
that antigen-specific  (DNA) selection occurs subsequent to 
this event (14). This process would yield IgM anti-DNA with 
the structural characteristics of a randomly selected popula- 
tion of DNA-specific antibodies and IgG anti-DNA with the 
structural characteristics of a clonally selected population of 
antibodies.  Our results are not consistent with this hypoth- 
esis. Although the results cannot exclude the existence of a 
population of polyclonally activated B cells in the (NZB  x 
NZW)F1 mice used in this study, they suggest that both the 
IgM and IgG anti-DNA hybridomas were derived from B 
cells stimulated by antibody receptor-specific  events. As dis- 
cussed below, those events were probably antigen-specific stim- 
ulation, most likely by DNA or complexes containing DNA. 
Previous analyses of V gene diversity among autoimmune 
anti-DNA antibodies have demonstrated preferential expres- 
sion of V. genes from the V.558 family (9, 25, 52). Radic 
et al. (25) estimated that 15 V8558 genes may encode anti- 
DNA (95% C1  =  9, 42). Using the identical pair method 
(18), we estimated the number of V8558 genes that could 
encode anti-DNA to be 24 (95% CI =  15, 36), which agrees 
reasonably well with the previous estimate.  The recurrence 
of particular V, genes among the anti-DNA hybridomas 
analyzed in this study is striking particularly when compared 
with the V. gene expression seen among anti-DNA hybrid- 
omas in previously published studies. A summary of the recur- 
rence of VH and V~ genes among all previously published 
spontaneous anti-DNA antibody variable region sequences 
is presented in Tables 2 and 3. The V, genes that were pref- 
erentially expressed among the hybridomas sequenced in this 
study have been recurrent among the anti-DNA antibodies 
sequenced in other laboratories. Moreover, even the V. genes 
that were not preferentially expressed among our population 
of hybridomas are recurrent among the total murine popula- 
tion of anti-DNA antibodies for which VH sequences have 
been published (Table 2). Preferential expression of VL genes 
that has not previously been apparent among anti-DNA (9, 
25) could be identified here, because of the larger number 
of sequences analyzed in this study (Fig. 2). Those VL genes 
that are preferentially  expressed among the hybridomas in 
this study are recurrent among the total population of mouse 
spontaneous anti-DNA for which VL sequences have been 
reported (Table 3). Like the V. genes, even those V~ genes 
that were not preferentially  expressed among our popula- 
tion of hybridomas are recurrent in the total population of 
mouse spontaneous anti-DNA.  The V.558-VK1 and V,558-V~8 
combinations that were preferentially  expressed among the 
hybridomas analyzed in our studies have also been observed 
among previously analyzed anti-DNA hybridomas (7-9, 24). 
The recurrent nature of particular V.-V~ combinations 
and individual V, and VL genes,  as described above, is in- 
dicative of a strong preference for these variable region struc- 
tures among anti-DNA hybridomas. The rather large number 
of V. and Vc genes that can potentially generate an anti- 
DNA antibody indicates that there is no V, or Vc gene re- 
striction for the generation of these antibodies. Even the most 
highly represented V. and VL genes were found in only 13% 
and 11% of the clones, respectively.  Rather,  the recurrent 
and preferential use of particular Va-VL  combinations is more 
consistent with clonal selection of anti-DNA B cells through 
antibody receptor-mediated events. As discussed below, the 
most likely event to control such selection is antigen-specific 
selection by DNA or DNA complexes. The lack of V. and 
Vc restriction is consistent with results from previous studies 
of V. gene diversity among anti-DNA hybridomas from an 
individual (NZB  x  NZW)Fx mouse (10) and from MILL 
Ipr/lpr mice (9). Therefore, as previously discussed in detail 
(7, 9), shared idiotypy among anti-DNA (5, 53-57) is un- 
likely  to  result  from V.  or  V~ gene restriction.  Rather, 
shared idiotypy among anti-DNA is more likely related to 
structures that control the specificity of anti-DNA (9). 
All the clones with the junctionally derived arginine in 
JK1 produce anti-DNA antibodies that bind dsDNA (Table 
1, and Jou et al., manuscript in preparation). Moreover, this 
same J~l arginine has appeared in the anti-DNA hybridoma 
DNA4 and the clonally related hybridomas DNAS, DNA6, 
and DNA7 from our laboratory,  and among anti-DNA hy- 
bridomas from other laboratories: B62 (29) and BxW-DNA14 
(22) from (NZB  x  NZW)Fg  13 and 30 from (SWR  x 
NZB)F1 no. 7 (27);  and 2Bll from BALB/c (58).  All the 
monoclonal anti-DNA with J~l that have arginine at posi- 
tion 96 bind dsDNA. These results suggest that arginine at 
position 96 in VL CDR3 may be a highly selected structure, 
especially for dsDNA binding. The canonical  L chain for 
Id  TM antiarsonate antibodies also has an arginine at position 
96 in VL CDR3 that appears to be generated from  junctional 
diversity (59).  This VL structure is highly selected among 
antiarsonate antibodies.  Arginines in both VH CDR3 and 
position 96  VL  CDR3  are  generated by  random,  non- 
template-encoded processes (7, 9,  24, 25, 29) and are rela- 
tively rare among antibodies in general (9). Therefore, there 
772  Clonally  Selective Stimulation of IgM and IgG Anti-DNA Table  2.  Recurrent Va Gene Usage among Spontaneous Anti-DNA Autoantibodies 
Relevant dunes  Hybridomas or dunes 
VH gene group*  from Fig.  1'  from other laboratodesS  Reference 
VH588-BWDNA16  165.14, 17s.128  BXW-DNA16  22 
A52  24 
C72  29 
BV16-19  26 
17s-cl,  165.60  Clones H  and I, 82-3  25 
H130  23 
A6.1  67 
-2F2(3H9)  17s.c4, 17s.13  Clones A, B, and E; D20  9 
Clone 4  7 
-MRLDNA22  111.185, 165.27,  MRL-DNA10,  MRL-DNA22  22 
165.49, 17s.83 
163.100  564, 550, 567, 563  27 
05,  11,  12 
-BWDNA7  111-cl,  111-c2, 17p.101  BXW-DNA7  22 
202.80, 202.s38, 202.135  8-1, D30  25 
202.61, 165.3m  D444, D44  24 
BWR4  29 
-$57(Vh31)  17s-c2, 165.3, 74-cl  Clones C  and F  9 
Vx7183-Vh283  163-cl,  83-cl  Clone D, DP12,  $106  9 
33-2  25 
-DNA13  17.s130  Clone 3, DNA3, DNA4  7 
VHS107-Vh11  163-c2, 74-c2, 111.33  D42  24 
B62  29 
DP1  9 
Clones 1-7  28 
VHQ52  163-c3  D23  84 
9-15, 9-4  50 
Val0  17ps-c7  MRL-DNA4  83 
BV04-01  26 
* The V. gene group refers to the reference sequences used in Fig. 1. 
Relevant sequences from Fig. 1 are clones that share the indicated V gene sequence. 
S  The clones or hybridomas indicated (from previous publications indicated  by the reference) are homologous to the indicated  V region sequence. 
must be a strong selection for DNA-specific B cells with an- 
tibody receptors that have arginines at these positions. 
Because of its basic charge and potential ability to form 
hydrogen bonds with either G-C base pairs through the major 
groove or phosphate groups on the backbone of dupl~ DNA, 
arginine has been predicted to be important for protein binding 
to DNA (60). Direct evidence for such a role of arginine in 
anti-DNA mAb BV04-01 has been demonstrated (61). There- 
fore, sdection for one or more arginines in VH CDR3 and 
at position 96 in VL CDR3 may occur because arginines at 
these positions increase the potential for DNA binding by 
the respective  antibodies. Mutations that result in arginine 
replacements in VH CDR have been demonstrated to have 
marked effects on the specificity and relative af~nity of anti- 
DNA antibodies (7, 8, 25, and Jou et al., manuscript in prep- 
aration). Moreover, the most frequent replacement mutations 
among anti-DNA antibodies are to arginine or asparagine 
(25), another amino acid predicted to be particularly impor- 
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Relevant clones  Hybridomas or clones 
V. gene group*  from Fig.  1'  from other laboratoriesS  Reference 
VK1-MRLDNA4  17s-c2, 17s-c3, 17s-c5  MRL-DNA4, MRL-DNA10  22 
17s.93,  17s.13  DP1,  1E81  9 
BV16-19, BV04-01  26 
202.s38,  111.68  BV17-31  26 
VK8-DNA5  202.9,  165.45, 165.49, 163-cl  Clone 4  7 
111-cl,  165.3, 165.5  Clone G  9 
D23  84 
Group  1  28 
202.135  A52  24 
Clone C, D20  9 
VK2-BWDNA14  17.p3,  111-c2, 17s.145  BXW-DNA14  22 
B62  29 
D23  9 
VK4/5-DNA22  163.72  MILL-DNA22  22 
Group  3  28 
17s-c6  BWR4  29 
VK9-DNA13  163.47  DNA13  7 
33-2  25 
VK10-v-16 
DNA3,DNA4  7 
8-1  25 
Vs21-V~21E  17s-c4  05,  11,  12  27 
VK23-DP12  165.60,  165.6  DP12  9 
Clone I  25 
165.54  D444  24 
VKOx-l-45.21.1  202.61  564, 550, 567, 563  27 
163.42  BWR5  29 
* The VL gene group refers to the reference sequences used in Fig. 2. 
Relevant sequences from Fig. 1 that share the indicated V gene sequence. 
5 The clones or hybridomas indicated (from previous publications indicated by the reference) are homologous to the indicated V region sequence. 
tant for protein binding to DNA (60). An asparagine in the 
binding site of mAb BV04-01 has also been demonstrated 
to participate in the binding of DNA by this mAb (61). 
In light of these observations, the comparison of consensus 
VH and VL CDR sequences generated from all of the mAbs 
in this study generates very interesting results.  To generate 
these results,  all of the mAbs in Table 1, which would in- 
dude all of the individual members of the multiple member 
clones  (Jou et al.,  manuscript  in preparation),  were sorted 
into one of three categories:  loDNA, ssDNA, and dsDNA 
(Fig.  4). The loDNA category consists of those mAbs that 
were not competitively inhibited from binding by g2/~g/ml 
of either ssDNA or dsDNA in the competitive ELISA. There 
are 14 IgM and two IgG mAbs in this group. The ssDNA 
group consists of those mAbs that were competitively in- 
hibited by g2/~g/ml ssDNA but not dsDNA. There are 15 
IgM and 31 IgG mAbs in this group. The dsDNA group 
consists of those mAbs, five IgM and 33 IgG, that were com- 
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loDNA 
ssDNA 
dsDNA 
CDRI  CDR2  CDR3 
1  ii 
3  3  5  5  5  56  6  9  90  00 
1  5  0  2abc3  90  5  5  90abc  ijkl2 
SYGMH  GI-P--GGG-TYYNDKFKG  Y---G---Y  WYFDY 
SY-MN YINPGAGSGGTYYNEKFKG  GGY-GGSY-Y  YYFDY 
SYAMS  YISPKAGGGGTYYNDKFKG  H-YGG~Y-  YYFDY 
dsDNA 
-vh558  DYYM-  YINP  -NGGTKYN-KFKG  GGY-GDG  -YAFDY 
-vh7183  SYAMS  YIS-  GGGSTYYPDSVKG  HYYGS~TY  --YFDY 
-vhSl07  DYYMN  LIRNKANGYTTEYSASVKG  DPYGR~S  -TMDY 
-vhQ52  SYAIS VIWT  GGDTSYNSALKS  NTPLG~Y  YFDY 
VL 
CDRI  CDR2  CDR3 
2  23  35  5 
7abcdef8  0  4  0  6 
RSSQSLLNSRTGKNYLA  WAS  -RES 
RS  S  QS  LVHSRNGNTYLH KVSNRFS 
R-SQS  LLNSR~KNYLA  WASTRAS 
89  9 
90  7 
QQSY-LPQ-T 
QQSTHVP--T 
KQS  Y~LP NT 
-ASQSLLKSR~SSYLH  S-SNL-S 
KSSQSLLNSRH~KNYLA  WASTRES 
RASQ  NINIWLS KTSNLHT 
R-SEGAV  NIYSYLA NAKTLAE 
HQSH~SP ~T 
KQS~p 
LQGQTYP ~T 
QHHYGTP PT 
Figure 4.  Consensus VH and VL CDK 
amino acid  sequences  for anti-DNA antibodies 
grouped according to the criteria  described  in 
the text. Determination  of  CDR regions  is ac- 
cording to Kabat et al. (42). The vertically 
aligned numbers and letters at the top of the 
figure indicate  amino acid positions (42). The 
V, gene family representation among anti- 
bodies in the dsDNA group was 14 V.558, 12 
V,7183, 9 V~Q52, and 3 VsSI07. The V~ 
composition was 5 V,5; 12 V~8; 8 V,12; 3 
V,10; 2 each V,9, Vxl, and Vx2; and 1 each 
V,I, V~Oxl, V~21, and V~19. 
petitively inhibited by g2/~g/ml dsDNA. Of the 107 mAbs, 
seven were not included because either the VH or VL se- 
quence was incomplete for e'~.h. The VH and VL CDR amino 
acid sequences for the mAbs in each of the three groups were 
aligned (42), and consensus CDR sequences for both VH 
and VL were generated for each group. Since there were two 
Phosphate 0 
L-Arg 29 
Phosl: 
H-  1 
Figure 5.  A hypothetical,  computer-generated  model  ofanti-DNA an- 
tibody binding to duplex, B form DNA. A model of the 163] mAb Fab 
is presented  as a stick figure of the c~-carbon  amino acid chain without 
K groups. The model is based on the crystallographic  coordinates  for the 
mAb HyHEL5 (62). The DNA model is that for 16 bp of poly(dA-dT)- 
poly(dA-dT), B form, double-hdical  DNA (supplied  with the software). 
Those amino acids in positions  that would allow hydrogen  bonding with 
the indicated phosphate oxygens  on the DNA backbone are represented 
as dotted Van der Waals spheres of the R. groups. The view presented 
is perpendicular  to the linear axis of the DNA. Facing the model, H-Arg 
100, bArg 29, and L-Asn 31 are on the front side of the doable helix, 
and H-Lys  50 and H-Set 52a are on the back side. The model was gener- 
ated with the SYBYL  software  package  (Tripos  Associates, Inc., St. Louis, 
MO) running on a Sun 4-260 and displayed  on an Evans and Sutherland 
PS390 graphics display terminal. 
large clones in the dsDNA group (163-cl  and t85-cl), con- 
sensus CDR sequences were also separately generated for the 
dsDNA mAbs according to V. gene family expression to de- 
termine how the large clones might bias  the dsDNA con- 
sensus.  163-cl has a V.7183 V.,  and 185-cl, a VaQ52 V.. 
As the results demonstrate (Fig.  4), the consensus VH and 
VL were representative of more than just the large clones. 
Comparison of the consensus CDR sequences for the three 
specificity groups of anti-DNA mAbs (Fig. 4) reveals that 
the loDNA group of  mAbs was the most variable. The ssDNA 
group and dsDNA group have very similar consensus VH 
CDR1 and two but considerably different VH CDR3. Most 
interesting are the consensus arginines at positions 100 and 
100a  in  the  dsDNA  group.  The  consensus  arginines  at 
positions 100 and 100a do not necessarily imply that most 
dsDNA-specific mAbs in our population have arginines at 
both positions. Rather, as the consensus for each V. family 
demonstrates, most of the antibodies have arginine at one 
or the other position. Although 7 of 16 loDNA and 25 of 
46 ssDNA mAbs also have arginines in VH CDR3, the argi- 
nines in VH CDR3 among these two groups are more ran- 
domly distributed. The anti-DNA mAb from DNA3, DNA4, 
and all the hybridomas in clone 3 previously analyzed in our 
laboratory (7) have arginines at one or both positions 100 
and 100a in VH CDR3, and they all bind to dsDNA with 
high avidity. Several anti-DNA mAbs from other laborato- 
ries that bind to dsDNA also  have one or more arginines 
at positions 100 to 100a in VH CDIL3: clone F (9); done 
1 (28); and B62 and C72 (29). Although 24 of  38 IgG dsDNA- 
binding mAbs  indicated in Table 1 have arginines in VH 
CDR3 between positions 99 and 100b, there are exceptions. 
Of the exceptions, only four have VH CDR3 without ar- 
ginines. 
The comparison of consensus VL CDK sequences indi- 
cates that the loDNA VL consensus is very similar to that 
for the dsDNA group, with the exceptions of position 29 
in VL CDR1, position 55 in CDR2,  and positions 89 and 
93 in CDR3. The consensus VLs for both the IoDNA and 
dsDNA groups are similar to the V~8 sequence of DNA5 
(Fig. 2 B), with the differences noted above. The consensus 
VL for the ssDNA group is nearly identical to that of VA 
(Fig. 2 A). These consensus sequences are consistent with 
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groups.  Of 20 mAbs with a VK8 VL,  12 bind strongly to 
dsDNA, while only 1 of 26 mAbs with a VK1 VL binds 
strongly to dsDNA (Table 1, and Jou et al., manuscript in 
preparation).  Five  mAbs with V,5 VL also bind to dsDNA 
very well (Table 1, andJou et al., manuscript in preparation). 
Of the five V,5 mAbs, four have an arginine at position  29 
in  VL  CDR1  analogous  to  the V~8  mAbs  that bind  to 
dsDNA strongly (Fig. 2, B and D). The mAb from 202.135 
and all of those from the hybridomas in clone 111-cl have 
V,558-BWDNA7 and V~8-DNA5 (Figs. 1 A and 2 B). The 
VH CDK3 for both clones are similar as well. The mAbs 
from 111-cl all bind dsDNA (Jou et al., manuscript in prepa- 
ration), whereas the mAb from 202.135 only binds to ssDNA. 
Given the above results, the difference in VL CDR1 position 
29 between these two clones may contribute in part, if not 
totally, to the difference in DNA binding by these mAbs, 
although there are other sequence differences between these 
two clones. A notable position in the consensus for dsDNA- 
binding mAbs with VH from the V.558 family is position 
96 in VL CDR3. The consensus for this group at that posi- 
tion is an arginine. As detailed above, arginine at this posi- 
tion is probably generated by junctional diversity in the first 
codon of J~l. 
The VH and VL CDR sequences for the mAbs from clone 
163-cl  are nearly identical  to the consensus sequences for 
V,7183 dsDNA-binding antibodies (Fig. 4). Of nine mAbs 
from this clone, eight bind to dsDNA with relatively high 
avidity (Table 1, and Jou et al., manuscript in preparation). 
A computer model of one of the mAbs from clone 163-cl, 
163.1, was generated using the crystallographic coordinates 
for  the  antilysozyme mAb  HyHEL5  (62) (Fig. 5).  The 
hypothetical  binding of a model of poly(dA-dT)-poly(dA- 
dT) to the antibody-combining site was obtained by docking 
the DNA with the antibody-combining site. This DNA forms 
a normal B form double helix.  The amino acids predicted 
by the computer model to be in positions to form hydrogen 
bonds with either base pair or backbone  structures  of the 
DNA are identified in Fig. 5. As the model illustrates, lysine 
at position  50, serine at position  52a, and arginine at posi- 
tion 100 in the heavy chain, and arginine at position 29 and 
asparagine at position 31 in the light chain, are each in a po- 
sition that would allow them to form hydrogen bonds with 
phosphate  oxygens on the DNA backbone.  The arginines 
in VH position 100 and VL Position 29 correspond to residues 
that were predicted by the dsDNA group consensus sequence 
(Fig. 4) to be important for dsDNA binding.  Among the 
eight hybridomas clonally related to 163.1, a shared somatic 
mutation at VH position 50 and a unique mutation at VH 
Position 52a can be directly correlated to differences  in dsDNA 
binding by the respective mAbs (Jou et al., manuscript in 
preparation).  Therefore,  the amino acids predicted by the 
hypothetical  model to be responsible for DNA binding by 
mAb 163.1 are the same ones that have been predicted  to 
be important for dsDNA binding by structural and serolog- 
ical analyses of the mAbs from clone 163-cl. 
The pathogenetic potential of the mAbs described in this 
report to initiate autoimmune disease has not been directly 
tested. O'Keefe et al. (63) have used the criterion of variable 
region cationicity, characteristic of antibodies expressing the 
Id564 idiotype, as an indicator of pathogenicity.  Based upon 
this criterion, many of the mAbs described here and certainly 
the antibodies that bind to dsDNA with relatively  high avidity 
would be expected to be pathogenic,  as would most of the 
dsDNA-binding antibodies that have been reported by others, 
such as A52 (24), mAbs from clone A (9), and mAbs from 
clone H (25). This criterion is certainly consistent with the 
original observations of Ebling and Hahn (64) and Dang and 
Harbeck (65) that the anti-DNA antibodies  deposited  in 
nephritogenic mouse kidneys are cationic. The selection for 
basic amino acids within the V regions of most anti-DNA 
antibodies demonstrated here and by others (6, 7, 9, 24, 25, 
29) may account for the cationicity of pathogenic anti-DNA 
antibodies. Of those anti-DNA mAbs that have been directly 
demonstrated to initiate or accelerate nephritis,  H130 (66), 
A6.1, and 3GB3 (67) have a neutral pI. Therefore, determi- 
nation of pathogenicity among anti-DNA mAbs cannot be 
related only to pI or idiotype expression (66, 67). Moreover, 
the formation of glomerular immune deposits by the mAbs 
H130, H241 (66), and A52 (68) were independent of DNA 
binding by the mAbs.  These observations lead to the in- 
teresting hypothesis that the production of anti-DNA anti- 
body is induced and sustained by DNA or DNA complexes, 
but pathogenesis may occur independently of DNA binding. 
Clearly future experiments  will be needed to sort out the 
structural basis for the pathogenicity of anti-DNA antibody 
in lupus  nephritis. 
The most common feature among anti-DNA antibodies 
as demonstrated here and elsewhere (6-9, 24-27,  29, 69) is 
the selective expression of VH and VL structures that would 
be predicted and in some cases can be demonstrated to influence 
specificity for DNA. Although these results cannot rule out 
other structurally selective mechanisms such as idiotype net- 
works and DNA crossreactive antigens that may contribute 
to the generation of anti-DNA, they are most consistent with 
the hypothesis that anti-DNA originates and is sustained by 
an antigen-specific immune response to DNA, most likely 
in a complex with proteins that could provide the necessary 
source for a T, epitope. 
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